NCT02261974View on ClinicalTrials.gov

VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness

NACompletedINTERVENTIONAL
Enrollment

186

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Vaginal Laxity Following ChildbirthSexual Function Following Childbirth
Interventions
DEVICE

Active Treatment Viveve

Subject will receive 90 Joules/cm2 radiofrequency energy to the vaginal introitus

DEVICE

Sham Treatment Viveve

Subject will receive ≤ one (1) Joule of radiofrequency energy to the vaginal introitus

Trial Locations (9)

AB T2 7G9

Allan Centre, Calgary

H4R 0B7

Complexe Medical St-Laurent, Montreal

QC H3 A1 T5

Les Cours Medical Centre, Montreal

Unknown

Exogenia Institute of Anti-Aging and Regenerative Medicine, Sherbrooke

Research Center of Reproductive Medicine. - IRCCS Policlinico San Matteo Hospital, Pavia

Yokohama Motomachi Jyosei Iryou Clinic Luna, Kanagawa

Naoe Beauty Clinic, Tokyo

Instituto Palacios, Salud de la Mujer, Madrid

Unidad de Gestión Clínica de Obstetricia y Ginecología. Hospital Universitario Araba, Vitoria-Gasteiz

All Listed Sponsors
lead

Viveve Inc.

INDUSTRY

NCT02261974 - VIveve Treatment of the Vaginal Introitus to EValuate Effectiveness | Biotech Hunter | Biotech Hunter